David Surguladze

David Surguladze, M.D., has more than 22 years of industry experience in preclinical drug discovery and development. He has extensive leadership experience having held positions of increasing responsibility throughout his career. Prior to joining HiberCell, David served as Director of Preclinical Pharmacology at Eli Lilly and Company, where he was responsible for preclinical evaluation of a diversified portfolio of novel cancer therapeutics that included small molecules, biologics, and ADCs. Additionally, he provided support for translational biomarker identification and patient tailoring strategies working closely with members of other multidisciplinary teams, as well as utilizing external resources through CROs. As a senior scientist at Nobex Corporation, he guided preclinical drug development efforts from target identification through IND submission for multiple programs in the areas of inflammation, diabetes and CNS disorders. During David’s scientific career, his efforts have led to 15 IND submissions and 2 marketed therapies for cancer – Cyramza and Portrazza. He has authored multiple peer-reviewed publications, a book chapter, and several patents.

David is a certified general surgeon and earned his M.D. in Georgia from Tbilisi State Medical University.